David Parks - Concepedia

Author

David Parks

GlaxoSmithKline (United Kingdom)

Also Known As

David J. Parks, David Parks

Publications

660

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)ViiV Healthcare (United Kingdom)Janssen (Belgium)Queen Mary University of London Hospital Universitario La Paz

About

David Parks is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, hiv, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	557
2	Public Health	1	1	371
3	Pharmacology	1	1	371
4	Antibiotics	1	1	76
5	Clinical Epidemiology	1	1	371

David Parks

Publications

660

Citations

H-Index

Page 1

	Year	Citations
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, The Lancet Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical Trials	2018	371
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies Michael Aboud, Chloe Orkin, Daniel Podzamczer, The Lancet HIV Treatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirology100-Week Data	2019	110
Comparison of Topical Ciprofloxacin to Conventional Antibiotic Therapy in the Treatment of Ulcerative Keratitis David Parks, Donald A. Abrams, Faith A. Sarfarazi, American Journal of Ophthalmology AntibioticsConventional Antibiotic TherapyTopical CiprofloxacinTopical DrugContact Dermatitis	1993	76
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health Grace A. McComsey, Sergio Lupo, David Parks, AIDS	2017	56
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials Jean van Wyk, Chloe Orkin, Rafael Rubio, JAIDS Journal of Acquired Immune Deficiency Syndromes	2020	47

Page 1